Objective-To investigate the role of serial measurement of urine neopterin concentration in monitoring the progression of systemic lupus erythematosus (SLE) disease activity scored using the British Isles Lupus Assessment Group (BILAG) index.
other study parameter (ESR and serum C3, C4, and C3d) mirrored SLE disease activity as effectively. Conclusions-This study provides initial evidence that changes in urine concentrations of neopterin are significantly correlated with fluctuations in disease activity over time, scored using the BILAG index, amongst individual patients with SLE. Consequently, serial urine neopterin measurements appear to be clinically useful for monitoring disease activity and may contribute substantially to therapeutic decision making in these patients. (Ann Rheum Dis 1994; 53: 743-748) A challenge in the clinical management of patients with systemic lupus erythematosus (SLE) is to identify laboratory parameters that will distinguish those with active and those with inactive disease, and parameters that can be used to monitor serially disease activity and disease progression. Erythrocyte sedimentation rate (ESR), serum or plasma complement concentrations, and antibodies to double stranded DNA (dsDNA) are currently used in clinical practice as markers of disease activity. However, some patients can have persistently abnormal results in these tests and yet show few clinical symptoms or functional deterioration of a major organ, whilst other patients are severely ill with only minimal changes in these parameters. Moreover, some parameters are only useful in certain patterns of organ involvement in SLE; for example, changes in anti-dsDNA and complement concentrations are reported predominantly to accompany flares of lupus nephritis. l 2 Urine neopterin, an indirect marker of the upregulation of the cellular immune system,3
has previously been demonstrated to be of value as a parameter of disease activity in an unselected group of SLE patients. Urine neopterin measurements were made at varying intervals and over a period of months. In order to study the temporal relationship between urine neopterin concentration and SLE disease activity, the data set was therefore modelled as a time series. 8 Initially, an analysis of covariance was carried out to assess the relationship between BILAG score and patient factors. In this model, time and patient were included as factors, urine neopterin as a covariate and BILAG score as the dependent variable. The initial assessment for each patient was numerically coded 0, with subsequent consecutive assessments coded 1, 2, 3, etc, and only patients with more than five assessments each were included into the model. Where time was found not to have a significant effect, the association between the mean BILAG score and the mean urine neopterin value for each patient was then examined by regression analysis. Similar analyses were carried out for ESR and plasma C3, C4 and C3d. For these analyses, the SPSSx' software package was used;9 p < 0 05 was considered significant.
Results
Of the 68 patients, 35 had more than two assessments (nine had three, seven had four, five had five, four had six, seven had seven, one had eight and two had 10 assessments) during the study period. According to the BILAG index, 116 of these assessments were defined as active and 117 were inactive. Twenty five patients had active disease involving more than one organ system and 24 had active disease involving one organ system only. Active disease involved the general system in 10 patients, the mucocutaneous system in 24, the central nervous system in nine, the musculoskeletal system in 18 patients, the cardiorespiratory system in six, vasculitis in 12 patients, the renal system in three, and the haematological system in 17 patients, either in isolation or as part of multiple organ system disease.
At the time of initial evaluation, urine neopterin concentration was found to correlate significantly with the BILAG score (rs = 0-32, p = 0 008). Significant correlations were also found for C3 (rs = -0 38, p = 0 00 1), and C4
(rs=-0 45, p=0 0001), but not for ESR (rs = 0 09) or C3d (r, = 0 08).
URINE NEOPTERIN AND DISEASE FLARE
Fourteen patients had flares of their disease during the study period. Figure 3 shows the serial plots of urine neopterin and BIIAG score with time in 14 patients who completed more than five complete assessments each. In the analysis of covariance, with time and patient as factors, urine neopterin as a covariate and BIIAG score as the dependent variable, time did not have a significant effect and could therefore be ignored in the multivariate model ( (allowing for patient factors) (r = 0-6, p<O 05). In contrast, analyses of covariance of the relationship between the other test parameters (plasma C3, C4 and C3d, and ESR) and BILAG score, all revealed a significant effect of time (p < 0-05), but it was not feasible to define further this effect of time because of the relative paucity of the data sets.
Discussion
This study provides evidence that changes in urine concentrations of neopterin are significantly correlated with fluctuations in disease activity, scored using the BIIAG index, among individual patients with SLE.
Single time point analysis showed that urine neopterin was significantly increased during flares in SLE disease activity. Similarly, a 
was observed in patients with active SLE who went into disease remission. In those patients whose disease remained active or in remission on second successive assessments, urine neopterin concentrations were found to be correspondingly greater or smaller compared with initial values. In addition, a significant correlation between urine neopterin concentration and BILAG score underlined the association of urine neopterin with clinical activity in SLE.
In the clinical setting, however, serial measurements of laboratory parameters are normally made to monitor patients. A number of studies have tried to address the temporal relationship between SLE disease activity and serum concentrations of complement, complement split products, and anti-dsDNA.' 2 10 In those studies, only graphical presentations and single time point analyses were used to describe the data sets, though the study parameters were measured sequentially over a period of many months or years, leading to loss of sensitivity and the problem of dependence between test statistics. When clinical monitoring is based upon serial quantitative measurements, the detection and interpretation of abrupt changes in pattern of the data series are of paramount importance. Often, however, such series of data are difficult to interpret, as biological variations and errors arising in the collection, measurement and processing of the data and variations with time itself need to be taken into account. In this prospective study, we adopted time series modelling to investigate if serial measurements of urine neopterin could predict the BILAG score and hence SLE disease activity in individual patients.
The graphical plots of serial urine neopterin concentrations and BILAG score in individual patients, shown in figure 3, suggest close relationships between the two measurements and with time. However, analysis of covariance indicated that the time variable added nothing to the prediction based on the urine neopterin covariate. Consequently, the time variable was ignored in the subsequent regression model. This showed a statistically significant association between serial concentrations of urine neopterin and BILAG score, with an r value of 0-6 (p < 0.05). However, it should be noted that the entry point of each patient into the analysis was arbitrarily called "time zero", even though patient recruitment into the study took place over a period of months. This designation may have influenced the outcome of the time series modelling, but is inevitable in the clinical setting; the difficulty in analysing such data sets has been highlighted in other studies." Replication of these findings with a larger series of patients, using more regular measurements and a longer time frame, is required to validate our conclusions further.
None of the other study paramaters was found to mirror SLE disease activity as effectively as urine neopterin, using both single time point and time series analyses. Plasma C3 and C4 did not decrease significantly during SLE disease flares in individual patients, even though these two parameters correlated significantly with the BIIAG score. In contrast, both ESR and plasma C3d failed to correlate significantly with BIIAG score and their values in individual patients did not increase significantly during SLE disease flares. In corresponding analyses of covariance with serial measurements of ESR, plasma C3, C4, and C3d as covariates, time was found to have a significant effect on the BIIAG score.
SLE is a chronic disease with variable activity characterised by numerous and varied abnormalities of the immune system, in particular upregulation of T lymphocytes. 2 Recent attention has been focused on serum sIL-2 receptors, derived from surface bound IL-2 receptors on activated T lymphocytes in vivo, as a sensitive and more reliable index of clinical activity in patients with SLE and other rheumatic diseases.'3 However, in our experience, there was considerable overlap between serum sIL-2 receptor values in SLE patients with active and inactive disease,4 suggesting that other factors, particularly renal function, must have an important influence on serum concentrations of sIL-2 receptors.'4 15 Similarly, anti-dsDNA was found to be a poor discriminant of disease activity in our patient cohort. Thus neither sIL-2 receptor nor antidsDNA was included as parameters in this study. Neopterin is specifically produced by human macrophages when stimulated by interferon gamma released from activated T lymphocytes, '6 17 and is therefore an indirect marker of the upregulation of the cellular immune system. Urine neopterin concentration has been shown to correlate significantly with serum sIL-2 receptor concentrations.'8 It is, then, not surprising to find that urine neopterin is a more sensitive index of disease activity in SLE patients compared with established tests.
Our calculations were based on the BILAG index as the established index of SLE disease activity. The BIIAG index is one of three currently available activity scales that have been shown to be reliable both between and within raters,'9 the other two being Systemic Lupus Activity Measure (SLAM)20 and SLE Disease Activity Index (SLEDAI).21 High correlations between these three clinical activity scales have been demonstrated, suggesting that they are all measuring the same thing.22 Ideally, the reliability of our calculations should have been validated against another independent clinical activity scale. However, the inclusion of one or more of the study parameters in the other clinical activity scales makes them unsuitable for use as instruments to validate these as parameters of disease activity.
In conclusion, this prospective longitudinal study has indicated that serial urine concentrations of neopterin are significantly associated with SLE disease activity scored using the BIIAG index. Measurement of urine neopterin is non-invasive, relatively simple and inexpensive and appears to be clinically useful for isolated assessments of disease activity in addition to serial monitoring of disease activity in the management of patients with SLE. 
